Other Clinical Trial - Prospective, Non-interventional, Multi-center,

Status Completed

Clinical Trial Summary

The primary objective in this study is to collect post-marketing information on Riociguat safety.Thus, the information on adverse events (AEs) and adverse drug reactions (ADRs) that occur within the first 12 months and in the following 6 -year observation at most, after starting Riociguat treatment under the routine clinical practice will be collected. The secondary objectives are collecting information on Riociguat effectiveness, such as 6-Minute Walking Distance (6MWD) Test. Since it is assumed that Riociguat is for long-term use, information on Pulmonary Arterial Hypertension (PAH) clinical worsening will also be surveyed once a year.

Clinical Trial Description

This local, prospective, non-interventional, multi-center study includes patients treated with Riociguat for PAH. A total of 600 patients (valid for safety analysis) is planned to be included in 4 years. This study is performed as an "all-case investigation" therefore; all patients who receive Riociguat treatment for PAH need to be registered, in principle. The treatment should be performed based on the product label in Japan. The standard observation period will last for 12 months from starting Riociguat treatment. Safety and effectiveness will be evaluated at the 3rd and 12th month of treatment. In addition, the extension observation period will be carried out as long as Riociguat treatment continues or at most for more 6 years. The purpose is to collect information on safety and effectiveness, such as adverse events and clinical worsening of PAH, once a year. Combining the standard observation and the extension observation period the patient could be followed for at most 7 years. When Riociguat treatment is terminated, the observation of the patient ends. The investigator should record data for each patient, as defined in the protocol, using the Electronic Data Capture (EDC) system. The duration of the study is of approximately 8 years from PAH indication approval. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02428985
Study type	Observational
Source	Bayer
Contact
Status	Completed
Phase
Start date	June 29, 2015
Completion date	September 20, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04095286` - Relative Bioavailability Study of Marketed and Lower Dose Ambrisentan in Healthy Adult Participants	Phase 1
Enrolling by invitation	`NCT03683186` - A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension	Phase 3
Completed	`NCT02191137` - Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION)	Phase 4
Completed	`NCT01959828` - Confirmatory Study of IK-3001 in Japanese Subjects With Peri-/Post-op Pulmonary Hypertension Assoc. With Cardiac Surgery	Phase 3
Withdrawn	`NCT01202045` - Stress Echocardiography in the Detection of Pulmonary Arterial Hypertension in Systemic Sclerosis Patients	N/A
Completed	`NCT00963027` - Effect of Esomeprazole on the Pharmacokinetics of Oral Treprostinil	Phase 1
Completed	`NCT00963001` - Effect of Food on the Pharmacokinetics of Oral Treprostinil	Phase 1
Completed	`NCT01121458` - Clevidipine for Vasoreactivity Evaluation of the Pulmonary Arterial Bed	Phase 4
Terminated	`NCT00825266` - Insulin Resistance in Pulmonary Arterial Hypertension	Phase 4
Terminated	`NCT00384865` - A Study of Aspirin and Simvastatin in Pulmonary Arterial Hypertension	Phase 2
Active, not recruiting	`NCT03926572` - Acute Decompensation of Pulmonary Hypertension	N/A
Completed	`NCT02826252` - Examination of Ventavis (Iloprost) Inhalation Behavior Using the I-Neb AAD System in Patients With Pulmonary Arterial Hypertension When Switching the Iloprost Nebulizer Solution for Inhalation From 10 μg/mL (V10) to 20 μg/mL (V20)	N/A
Completed	`NCT02545465` - A Study to Understand the Treatment Patterns in Patients With Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension During a Switch of Treatment to Adempas in Real-life Clinical Practice	N/A
Recruiting	`NCT04498299` - Stress Echocardiography in Patients Recovery From Mild COVID-19 Illness
Recruiting	`NCT02558582` - Effect of Exercise Training in Patients With Pulmonary Hypertension	N/A
Active, not recruiting	`NCT02562235` - Riociguat in Children With Pulmonary Arterial Hypertension (PAH)	Phase 3
Completed	`NCT02755298` - Chronic Clinical Effect of Acetazolamide	Phase 2/Phase 3
Completed	`NCT02576002` - Epidemiology and Treatment Patterns of Paediatric PAH (Pulmonary Arterial Hypertension)	N/A
Terminated	`NCT03043976` - Using Step Count to Enhance Daily Physical Activity in Pulmonary Hypertension	N/A
Completed	`NCT01178073` - A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Prospective, Non-interventional, Multi-center, Post-authorization Safety Study of Riociguat for Pulmonary Arterial Hypertension (PAH) — JPMS-PAH

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms